<?xml version="1.0" encoding="UTF-8"?>
<ref id="b0820">
 <label>164</label>
 <element-citation publication-type="book" id="h0820">
  <person-group person-group-type="author">
   <name>
    <surname>Cao</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Liu</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Bai</surname>
    <given-names>T.</given-names>
   </name>
   <name>
    <surname>Fan</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Hong</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Song</surname>
    <given-names>H.</given-names>
   </name>
  </person-group>
  <chapter-title>editors. High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with coronavirus disease 2019. Open forum infectious diseases</chapter-title>
  <year>2020</year>
  <publisher-name>Oxford University Press US</publisher-name>
 </element-citation>
</ref>
